Clovis Taps Into Rich "A" Round, Grabs Licensing Rights to Improved Gemcitabine
This article was originally published in The Pink Sheet Daily
Executive Summary
Clovis takes over work on Clavis's pancreatic cancer drug and will develop a companion test to target patients who fare poorly on Lilly's current standard of care.
You may also be interested in...
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.
Clovis Oncology Seeks $149.5 Million IPO
The Colorado cancer drug maker is seeking financing through the public capital markets.